Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis
An erratum to this article was published (Rheumatology (Oxford), 2 May 2024 ↗)
Authors' conclusion
Despite being the largest GWAS on an MTX treatment outcome to date, no genome-wide significant associations were detected.
Study context
- Population
- Swedish early-RA patients initiating MTX in DMARD monotherapy as their first-ever DMARD
- Participants
- 3,902 patients
- Comparison
- Genetic predictors of MTX monotherapy persistence
- Outcome
- MTX treatment persistence: remaining on MTX with no additional DMARDs added
- Follow-up
- 1 and 3 years
Methodological detailspolygenic risk score, SNP-based heritability
- Polygenic risk score
- SNP-based heritability
Performance
As reported in the abstract
MTX treatment persistence
RA polygenic risk score (PRS) and persistence at 1 year, RR
0.98
0.96–1.01
RA PRS and persistence at 3 years, RR
0.96
0.93–1.00
Heritability of persistence at 1 year
0.45
0.15–0.75
Heritability of persistence at 3 years
0.14
0–0.40
Further findings
Persistence by RA serostatus (subgroups)
- Seropositive RA: results comparable with RA overall
- Seronegative RA: heritability estimates and PRS RRs attenuated towards the null
Original publication
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis. Rheumatology (Oxford). Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →